Taking into consideration the significance of CRC CSCs, our study aimed at the identification of the clinicopathological characteristics of a subgroup of LARC patients who achieved ypT3, showing a post-nCRT and TME tumor fragmentation response, as well as the evaluation of the association between CD133 and CD166 expression, survival parameters and clinicopathological characteristics and the assessment of the CSC biomarkers as valuable indicators of the nCRT tumor response. This evidence concerns the gene ALCAM and neoplasm.